| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
127,700,000 |
| Market
Cap: |
467.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.42 - $6.21 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 11.1 |
| Insider 6 Months : 11.1 |
| Insider 3/6 Months : 22.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Organogenesis Holdings is a regenerative medicine company engaged on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical and Sports Medicine markets. In the Advanced Wound Care market, Co. engages on the development and commercialization of a portfolio of cellular and acellular wound care offerings that treat patients from the earliest indication of impaired healing to wound closure. In the Surgical and Sports Medicine market, Co. engages on the development and commercialization of products that support the healing of musculoskeletal injuries, including chronic degenerative conditions such as osteoarthritis and tendonitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
252,264 |
252,264 |
252,264 |
252,264 |
| Total Buy Value |
$725,290 |
$725,290 |
$725,290 |
$725,290 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
3 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
25,000 |
405,000 |
836,786 |
| Total Sell Value |
$0 |
$127,535 |
$1,485,680 |
$3,367,400 |
| Total People Sold |
0 |
1 |
2 |
4 |
| Total Sell Transactions |
0 |
1 |
8 |
12 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Freedman Lori |
Chief Admin. and Legal Officer |
• – – |
2025-06-06 |
4 |
B |
$2.99 |
$26,949 |
D/D |
9,022 |
846,459 |
2.74 |
21% |
|
| Freedman Lori |
Chief Admin. and Legal Officer |
• – – |
2025-06-05 |
4 |
B |
$2.91 |
$413,625 |
D/D |
142,379 |
837,437 |
2.74 |
27% |
|
| Freedman Lori |
Chief Admin. and Legal Officer |
• – – |
2025-06-04 |
4 |
B |
$2.82 |
$284,716 |
D/D |
100,863 |
695,058 |
2.74 |
28% |
|
| Cavorsi Robert |
Vice President, Strategy |
• – – |
2025-03-09 |
4 |
D |
$5.16 |
$1,398 |
D/D |
(271) |
189,525 |
|
- |
|
| Driscoll Michael Joseph |
Director |
– • – |
2025-03-04 |
4 |
S |
$5.10 |
$127,535 |
D/D |
(25,000) |
166,879 |
|
27% |
|
| Cavorsi Robert |
Vice President, Strategy |
• – – |
2025-03-01 |
4 |
D |
$6.21 |
$4,142 |
D/D |
(667) |
189,796 |
|
- |
|
| Giacomin Jon L |
Director |
– • – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
49,575 |
192,198 |
|
- |
|
| Leibowitz Arthur S |
Director |
– • – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
49,575 |
237,186 |
|
- |
|
| Quintero Gilberto |
Director |
– • – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
49,575 |
190,245 |
|
- |
|
| Montecalvo Antonio S. |
Vice President, Health Policy |
• – – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
42,493 |
196,680 |
|
- |
|
| Bilbo Patrick |
Chief Operating Officer |
• – – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
184,136 |
949,062 |
|
- |
|
| Freedman Lori |
Chief Admin. and Legal Officer |
• – – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
162,047 |
594,195 |
|
- |
|
| Driscoll Michael Joseph |
Director |
– • – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
49,575 |
191,879 |
|
- |
|
| Gillheeney Gary S. |
President and CEO |
• • – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
708,215 |
3,515,323 |
|
- |
|
| Cavorsi Robert |
Vice President, Strategy |
• – – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
61,705 |
190,463 |
|
- |
|
| Francisco David |
Chief Financial Officer |
• – – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
165,156 |
559,095 |
|
- |
|
| Grow Brian |
Chief Commercial Officer |
• – – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
183,067 |
670,490 |
|
- |
|
| Korfin Michele Ilene |
Director |
– • – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
49,575 |
190,245 |
|
- |
|
| Lustig Garrett |
Director |
– • – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
49,575 |
76,914 |
|
- |
|
| Duraibabu Prathyusha |
Director |
– • – |
2025-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
49,575 |
198,219 |
|
- |
|
| Gillheeney Gary S. |
President and CEO |
• • – |
2025-02-16 |
4 |
D |
$3.70 |
$22,655 |
D/D |
(6,123) |
2,807,108 |
|
- |
|
| Grow Brian |
Chief Commercial Officer |
• – – |
2025-02-16 |
4 |
D |
$3.70 |
$2,427 |
D/D |
(656) |
487,423 |
|
- |
|
| Montecalvo Antonio S. |
Vice President, Health Policy |
• – – |
2025-02-16 |
4 |
D |
$3.70 |
$2,660 |
D/D |
(719) |
154,187 |
|
- |
|
| Francisco David |
Chief Financial Officer |
• – – |
2025-02-16 |
4 |
D |
$3.70 |
$2,975 |
D/D |
(804) |
393,939 |
|
- |
|
| Freedman Lori |
Chief Admin. and Legal Officer |
• – – |
2025-02-16 |
4 |
D |
$3.70 |
$2,390 |
D/D |
(646) |
432,148 |
|
- |
|
325 Records found
|
|
Page 1 of 13 |
|
|
0.01 (0.27%) 
